Logo image of AIM

AIM IMMUNOTECH INC (AIM) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:AIM - US00901B3033 - Common Stock

1.32 USD
+0.07 (+5.6%)
Last: 12/29/2025, 4:26:56 PM
Fundamental Rating

1

AIM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 530 industry peers in the Biotechnology industry. Both the profitability and financial health of AIM have multiple concerns. AIM does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year AIM has reported negative net income.
In the past year AIM has reported a negative cash flow from operations.
AIM had negative earnings in each of the past 5 years.
AIM had a negative operating cash flow in each of the past 5 years.
AIM Yearly Net Income VS EBIT VS OCF VS FCFAIM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

AIM has a Return On Assets of -391.52%. This is amonst the worse of the industry: AIM underperforms 95.47% of its industry peers.
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROIC N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AIM Yearly ROA, ROE, ROICAIM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

AIM has a better Gross Margin (71.07%) than 81.89% of its industry peers.
AIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 71.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AIM Yearly Profit, Operating, Gross MarginsAIM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K

More info and screens

0

2. Health

2.1 Basic Checks

AIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AIM has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, AIM has less shares outstanding
The debt/assets ratio for AIM is higher compared to a year ago.
AIM Yearly Shares OutstandingAIM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AIM Yearly Total Debt VS Total AssetsAIM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

AIM has an Altman-Z score of -162.69. This is a bad value and indicates that AIM is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -162.69, AIM is doing worse than 96.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -162.69
ROIC/WACCN/A
WACC8.3%
AIM Yearly LT Debt VS Equity VS FCFAIM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 0.10 indicates that AIM may have some problems paying its short term obligations.
AIM's Current ratio of 0.10 is on the low side compared to the rest of the industry. AIM is outperformed by 96.60% of its industry peers.
A Quick Ratio of 0.10 indicates that AIM may have some problems paying its short term obligations.
With a Quick ratio value of 0.10, AIM is not doing good in the industry: 96.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.1
Quick Ratio 0.1
AIM Yearly Current Assets VS Current LiabilitesAIM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 58.16% over the past year.
Looking at the last year, AIM shows a very negative growth in Revenue. The Revenue has decreased by -15.84% in the last year.
Measured over the past years, AIM shows a small growth in Revenue. The Revenue has been growing by 3.96% on average per year.
EPS 1Y (TTM)58.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%

3.2 Future

Based on estimates for the next years, AIM will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.08% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y77.28%
EPS Next 2Y37.74%
EPS Next 3Y24.93%
EPS Next 5Y15.08%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y-14.87%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AIM Yearly Revenue VS EstimatesAIM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 20M 40M 60M 80M
AIM Yearly EPS VS EstimatesAIM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -500 -1K -1.5K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AIM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year AIM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AIM Price Earnings VS Forward Price EarningsAIM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AIM Per share dataAIM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

AIM's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.74%
EPS Next 3Y24.93%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AIM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

AIM IMMUNOTECH INC

NYSEARCA:AIM (12/29/2025, 4:26:56 PM)

1.32

+0.07 (+5.6%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-17 2025-11-17/amc
Earnings (Next)03-30 2026-03-30/amc
Inst Owners3.76%
Inst Owner Change0%
Ins Owners3.72%
Ins Owner Change0%
Market Cap3.76M
Revenue(TTM)170.00K
Net Income(TTM)-16.17M
Analysts80
Price Target22.44 (1600%)
Short Float %0.48%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)46.29%
Min EPS beat(2)38.12%
Max EPS beat(2)54.46%
EPS beat(4)4
Avg EPS beat(4)35.78%
Min EPS beat(4)13.9%
Max EPS beat(4)54.46%
EPS beat(8)5
Avg EPS beat(8)11.51%
EPS beat(12)8
Avg EPS beat(12)8.7%
EPS beat(16)8
Avg EPS beat(16)0.86%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-8.33%
PT rev (3m)-85.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)87.81%
EPS NY rev (1m)-7.05%
EPS NY rev (3m)61.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-64.75%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.09
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.25
EYN/A
EPS(NY)-3.33
Fwd EYN/A
FCF(TTM)-3.95
FCFYN/A
OCF(TTM)-3.84
OCFYN/A
SpS0.04
BVpS-2.3
TBVpS-3.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -391.52%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 71.07%
FCFM N/A
ROA(3y)-132.89%
ROA(5y)-90.82%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.1
Quick Ratio 0.1
Altman-Z -162.69
F-Score3
WACC8.3%
ROIC/WACCN/A
Cap/Depr(3y)119.66%
Cap/Depr(5y)104.37%
Cap/Sales(3y)164.13%
Cap/Sales(5y)265.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.47%
EPS Next Y77.28%
EPS Next 2Y37.74%
EPS Next 3Y24.93%
EPS Next 5Y15.08%
Revenue 1Y (TTM)-15.84%
Revenue growth 3Y7.99%
Revenue growth 5Y3.96%
Sales Q2Q%-25.71%
Revenue Next Year-51.38%
Revenue Next 2Y-16.95%
Revenue Next 3Y306.65%
Revenue Next 5Y-14.87%
EBIT growth 1Y47.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year372.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y34.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.07%
OCF growth 3YN/A
OCF growth 5YN/A

AIM IMMUNOTECH INC / AIM FAQ

What is the ChartMill fundamental rating of AIM IMMUNOTECH INC (AIM) stock?

ChartMill assigns a fundamental rating of 1 / 10 to AIM.


What is the valuation status of AIM IMMUNOTECH INC (AIM) stock?

ChartMill assigns a valuation rating of 1 / 10 to AIM IMMUNOTECH INC (AIM). This can be considered as Overvalued.


Can you provide the profitability details for AIM IMMUNOTECH INC?

AIM IMMUNOTECH INC (AIM) has a profitability rating of 1 / 10.


What is the earnings growth outlook for AIM IMMUNOTECH INC?

The Earnings per Share (EPS) of AIM IMMUNOTECH INC (AIM) is expected to grow by 77.28% in the next year.